Maria Angeles Ceregido

TL;DR: The CoVLP+AS03 vaccine was effective in preventing Covid-19 caused by a spectrum of variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.

TL;DR: A randomized, placebo-controlled, observer-blinded phase 1/2 study was conducted to evaluate the safety and immunogenicity of GBP510 adjuvanted with or without AS03 in adults aged 19-85 years at 14 hospital sites in Korea as discussed by the authors .

TL;DR: The primary immunogenicity objective was to describe the neutralising antibody titres to the D614G variant 14 days after the second vaccination (day 36) in participants who were SARS-CoV-2 naive, and this objective described the safety profile in all participants, for each candidate vaccine formulation.

TL;DR: Tdap vaccination during pregnancy resulted in high levels of pertussis antibodies in cord blood, was well tolerated and had an acceptable safety profile, and supports the recommendation of Tdap vaccinations during pregnancy to prevent early-infant pertussi disease.

TL;DR: Pertussis antibodies transferred during pregnancy may decrease the risk of pertussis infection in the first months of life but interfere with the infant's ability to produce pertussIS antibodies, the clinical significance of which remains unknown.